{
  "trial_id": "NCT02118012",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Adults, ages 18 and above",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Chronic hepatitis C (HCV RNA in serum for more than 6 months)",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "HCV RNA in serum at or above 10,000 IU/mL",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Treatment naive patients defined as individuals whom have never undergone any form of interferon and ribavirin therapy for chronic HCV infection or relapsers defined as reappearance of HCV RNA in serum after treatment (with any form of interferon and ribavirin therapy) was discontinued and an end-of-treatment response was achieved",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "No major contraindications to agents being used (chlorcyclizine HCl and ribavirin)",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Liver or any other organ transplant (including hematopoietic stem cell transplants) other than cornea and hair",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "64",
    "trial_id": "NCT02118012",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}